PHI-501, a novel and potent pan-RAF inhibitor in metastatic melanoma

被引：0
|
作者：
Kim, Namkyeong
Park, Jung Hee
Nam, Ky-Youb
Han, June H-J
Kim, Kyu-Tae
Sengupta, Sandip
Yoon, Jeong Hyeok
Sim, Taebo
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1627
引用
收藏
页数：2
相关论文
共 50 条
  • [21] JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models
    Hauptschein, Robert
    Woodcock, Simon
    Belfield, Andrew
    Mason, Helen
    Keppel, Dorottya
    Markova, Svetlana
    Kim, Kyuri
    Roller, Shane
    Phillips, Caroline
    Jones, Clifford D.
    Humphreys, Robin C.
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in preclinical models of human RAF/RAS mutant melanoma
    Miller, Nichol L. G.
    Wang, Tim S.
    Severson, Paul
    Jiang, Ping
    Perez, Michelle
    Timple, Noel
    Kanouni, Toufike
    Franovic, Aleksandra
    Martin, Eric S.
    Murphy, Eric
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Exarafenib (KIN-2787) is a potent, selective pan-RAF inhibitor with activity in preclinical models of BRAF class II/III mutant and NRAS mutant melanoma
    Wang, Tim S.
    Lee, Catherine
    Severson, Paul
    Pelham, Robert J.
    Williams, Richard
    Miller, Nichol L. G.
    CANCER RESEARCH, 2023, 83 (07)
  • [24] Dual inhibitor of immunokinase and pan-RAF for the treatment of KRAS-mutated cancers
    Hong, Sungpyo
    Ahn, Soon Kil
    Kwon, Ho-Seok
    Park, Yongbin
    Ki, Min-Hyo
    Shin, Hee Jong
    CANCER RESEARCH, 2018, 78 (13)
  • [25] An Efficient Second-Generation Manufacturing Process for the pan-RAF Inhibitor Belvarafenib
    Zell, Daniel
    Dalziel, Michael E.
    Carrera, Diane E.
    Stumpf, Andreas
    Bachmann, Stephan
    Mercado-Marin, Eduardo
    Koenig, Stefan G.
    Zhang, Haiming
    Gosselin, Francis
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2021, 25 (10) : 2338 - 2350
  • [26] Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1
    Gao, Yu
    Wendt, Sophia
    Krohn, Saskia
    Alammar, Moosheer
    Junghanss, Christian
    Nolte, Ingo
    Escobar, Hugo Murua
    ANTICANCER RESEARCH, 2024, 44 (09) : 3843 - 3848
  • [27] Development of a dual inhibitor of pan-RAF and VEGFR2 for the treatment of metastatic colorectal cancer with mutant K-RAS
    Hong, Sungpyo
    Choi, Young-Il
    Choi, Jihye
    Kim, Wonyoung
    Kwon, Ho-Seok
    Park, Yong Bin
    Ki, Min-Hyo
    Shin, Hee Jong
    Lee, Michael
    Ahn, Soon Kil
    CANCER RESEARCH, 2016, 76
  • [28] Discovery of TAK-632: A selective kinase inhibitor of pan-RAF with potent antitumor activity against BRAF and NRAS mutant melanomas
    Okaniwa, Masanori
    Hirose, Masaaki
    Arita, Takeo
    Yabuki, Masato
    Nakamura, Akita
    Takagi, Terufumi
    Kawamoto, Tomohiro
    Uchiyama, Noriko
    Sumita, Akihiko
    Tsutsumi, Shunichirou
    Tottori, Tsuneaki
    Inui, Yoshitaka
    Sang, Bi-Ching
    Yano, Jason
    Aertgeerts, Kathleen
    Yoshida, Sei
    Ishikawa, Tomoyasu
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [29] A selective and potent pan-RAF inhibitor, HM95573 exhibits high therapeutic potential as a next-generation RAF inhibitor by direct inhibition of RAF kinase activity in BRAF or RAS mutant cancers
    Namgoong, G.
    Kim, S. H.
    Song, T. H.
    Bae, I. H.
    Ahn, Y. G.
    Lee, J. H.
    Choi, K.
    Lee, K. H.
    Kim, Y. H.
    Lee, Y. M.
    Suh, K. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S127 - S127
  • [30] Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance
    Zhang, Yanmin
    Wang, Lu
    Zhang, Qing
    Zhu, Gaoyuan
    Zhang, Zhimin
    Zhou, Xiang
    Chen, Yadong
    Lu, Tao
    Tang, Weifang
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2017, 57 (06) : 1439 - 1452
12345